Myozyme øger overlevelsestiden betydeligt hos patienter med Pompes sygdom med debut i spædbørnsalderen.
In the first main study, which involved babies less than six months old, all 18 patients treated with Myozyme were alive at 18 months of age, and 15 of these did not need ventilation.